Skip to content

Study on the Clinical Characteristics, Genetic and Hereditary Features of Erythropoietic Protoporphyria (EPP) in the Chinese Population and the Efficacy and Safety of Red Blood Cell Exchange Transfusion for EPP

Study on the Familial Genetic Characteristics of Erythropoietic Protoporphyria (EPP) in Chinese Population and the Clinical Efficacy and Safety of Red Blood Cell Exchange Transfusion for EPP

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117357
Enrollment
Unknown
Registered
2026-01-22
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Porphyria

Interventions

EPP patient:N/A
Healthy Control :N/A

Sponsors

No. 900 Hospital of the Joint Logistic Support Force, People's Liberation Army of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria for the EPP Patient Group 1.Clinically confirmed diagnosis of EPP: Genetic sequencing reveals ferrochelatase (FECH) gene abnormalities; erythrocyte protoporphyrin levels are significantly elevated, 3–4 times higher than the normal reference value (< 80 µg/dL red blood cells). 2.Aged 18–75 years, with no gender restrictions. 3.Voluntarily sign the informed consent form and be able to cooperate with follow-up visits and relevant examinations. 4.No contraindications to red blood cell exchange transfusion, including severe coagulation disorders, severe anemia (hemoglobin < 80 g/L), hypersensitivity to blood products, and uncontrolled severe infections. Inclusion Criteria for the Healthy Control Group 1.No history of chronic diseases, including but not limited to cardiovascular diseases, liver diseases, hematological disorders, and porphyrias. 2.Erythrocyte protoporphyrin level < 80 µg/dL red blood cells. 3.Aged 18–75 years, with gender and age distribution matched to the EPP patient group. 4.Voluntarily sign the informed consent form. 5.Healthy blood samples from the hospital biobank are excluded. Given that free erythrocyte protoporphyrin is photolabile and susceptible to degradation over time, stored blood samples cannot guarantee the accuracy of test results. To ensure the reliability of research data, only fresh blood samples are collected.

Exclusion criteria

Exclusion criteria: Exclusion Criteria for the EPP Patient Group: 1.Complicated by cardiac, renal, cerebral or other severe organ failure: 2.Has contraindications to red blood cell exchange transfusion; 3.Pregnant or lactating women; 4.Those with acute episode complicated by severe infection and altered consciousness; 5. Those who refuse to cooperate with the collection of fresh peripheral blood and blood tests. Exclusion Criteria for the Healthy Control Group: 1.Meeting criteria 1–4of the exclusion criteria for the EPP patient group. 2.Having a family history of porphyria or relatives diagnosed with EPP. 3.Having a history of major surgery, blood transfusion, or administration of drugs that may affect porphyrin metabolism (e.g., certain antibiotics, antiepileptic drugs) within the recent 3 months. 4.Those who refuse to cooperate with fresh peripheral blood collection and blood tests.

Design outcomes

Primary

MeasureTime frame
Free Erythrocyte Protoporphyrin;

Countries

China

Contacts

Public ContactDongliang Li

No. 900 Hospital of the Joint Logistic Support Force, People's Liberation Army of China

1477931093@qq.com+86 136 6500 4967

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026